Condition
Crohn's Disease
Clear, practical articles to help you understand Crohn's Disease symptoms, medications, flares, nutrition, and everyday disease management. Browse our articles below.
Does Aetna Cover Tremfya for Crohn's Disease?
What Aetna's policy requires before it pays for Tremfya in Crohn's.
Does Aetna Cover Skyrizi for Crohn's Disease?
Aetna's Skyrizi coverage for Crohn's, decoded: the CPB, prior auth, and appeals.
Does Aetna Cover Omvoh for Crohn's Disease?
What Aetna requires to cover Omvoh for Crohn's, and how to appeal a step therapy denial.
Does Aetna Cover Entyvio for Crohn's Disease?
What Aetna requires before it pays for Entyvio in Crohn's, and how to appeal a denial.
Tysabri vs Tremfya for Crohn's Disease: Key Differences
Tysabri and Tremfya represent very different positions in the Crohn's biologic landscape. Tremfya (guselkumab) is an IL-23 p19-selective biologic approved for Crohn's in March 2025 based on GALAXI-2, GALAXI-3, and GRAVITI. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs tremfya crohn's comparison.
Tysabri vs Stelara for Crohn's Disease: How They Compare
Tysabri and Stelara take very different mechanistic approaches to moderate-to-severe Crohn's disease. Stelara (ustekinumab) is an IL-12/23 biologic that is widely prescribed for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. Both drugs are often considered in patients with complex treatment histories who have failed anti-TNFs or other options. This guide walks through the tysabri vs stelara crohn's comparison.
Tysabri vs Skyrizi for Crohn's Disease: Which to Choose?
Tysabri and Skyrizi represent two different generations and positions in the Crohn's biologic landscape. Skyrizi (risankizumab) is an IL-23 p19-selective biologic approved for Crohn's in June 2022 based on ADVANCE, MOTIVATE, and FORTIFY, increasingly prescribed as a first-line or second-line option. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs skyrizi crohn's comparison.
Tysabri vs Remicade for Crohn's Disease: Key Differences
Tysabri and Remicade are two IV biologics for moderate-to-severe Crohn's disease that take very different mechanistic approaches and differ sharply in how they are prescribed, monitored, and accessed. Remicade (infliximab) is a widely prescribed first-line IV anti-TNF biologic. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs remicade crohn's comparison.
Tysabri vs Omvoh for Crohn's Disease: A Comparison
Tysabri and Omvoh represent very different positions in the Crohn's biologic landscape. Omvoh (mirikizumab) is the newest IL-23 p19-selective biologic for Crohn's, approved in January 2025 based on VIVID-1. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk and typically reserved for refractory cases. This guide walks through the tysabri vs omvoh crohn's comparison.
Tysabri vs Humira for Crohn's Disease: A Comparison
Tysabri and Humira take very different mechanistic approaches to moderate-to-severe Crohn's disease, and they differ sharply in how they are prescribed, monitored, and accessed. Humira (adalimumab) is a subcutaneous anti-TNF biologic that is widely prescribed as a first-line biologic for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs humira crohn's comparison.
Tysabri vs Entyvio for Crohn's: Comparing Integrin Biologics
Tysabri and Entyvio both target integrins in the pathway that drives immune cell trafficking in Crohn's disease, but they differ in which integrin subunit they block, and that difference creates profoundly different safety profiles. Entyvio (vedolizumab) is gut-selective and has a favorable safety record. Tysabri (natalizumab) blocks a broader integrin target that includes trafficking to the brain, creating a risk of progressive multifocal leukoencephalopathy (PML) that requires the TOUCH program to manage. This guide walks through the tysabri vs entyvio crohn's comparison.
Tysabri vs Cimzia for Crohn's Disease: A Patient Guide
Tysabri and Cimzia are both less commonly prescribed biologics for moderate-to-severe Crohn's disease, each with specific niches in the treatment landscape. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic with a distinctive structure that makes it notable for pregnancy considerations. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to progressive multifocal leukoencephalopathy (PML) risk. This guide walks through the tysabri vs cimzia crohn's comparison.